MMCM
RARE icon

Murphy & Mullick Capital Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Murphy & Mullick Capital Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-100
Closed -$2.3K – 771
2025
Q4 		$2.3K Hold
100
– – ﹤0.01% 601
2025
Q3 		$3.52K Buy
+100
New +$3K ﹤0.01% 565

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Murphy & Mullick Capital Management's RARE Position: Q1 2026 in Review

Murphy & Mullick Capital Management sold out of Ultragenyx Pharmaceutical (RARE) in Q1 2026, closing a stake of 100 shares — an estimated $2.3K sold.

Murphy & Mullick Capital Management first reported a position in RARE in Q3 2025 and held it in 2 quarters. The position peaked at $3.52K in Q3 2025. 298 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • Murphy & Mullick Capital Management reported no remaining Ultragenyx Pharmaceutical position as of Q1 2026 after selling out during the quarter.
  • Murphy & Mullick Capital Management sold 100 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $2.3K.
  • Murphy & Mullick Capital Management first reported a position in Ultragenyx Pharmaceutical in Q3 2025 and held it in 2 quarters.
  • Murphy & Mullick Capital Management's Ultragenyx Pharmaceutical position peaked at $3.52K in Q3 2025.
  • 298 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Murphy & Mullick Capital Management's 13F filing for Q1 2026, filed 17 Apr 2026.